

# Marianna LucafÃ²

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7829705/publications.pdf>

Version: 2024-02-01

48  
papers

689  
citations

516710  
16  
h-index

642732  
23  
g-index

48  
all docs

48  
docs citations

48  
times ranked

1263  
citing authors

#	ARTICLE	IF	CITATIONS
1	Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab. Journal of Pediatric Gastroenterology and Nutrition, 2019, 68, 37-44.	1.8	41
2	Role of the Long Non-Coding RNA Growth Arrest-Specific 5 in Glucocorticoid Response in Children with Inflammatory Bowel Disease. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 87-93.	2.5	41
3	Study of a potential drug delivery system based on carbon nanoparticles: effects of fullerene derivatives in MCF7 mammary carcinoma cells. Journal of Nanoparticle Research, 2012, 14, 1.	1.9	38
4	New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles. PLoS ONE, 2013, 8, e74216.	2.5	34
5	Profiling the molecular mechanism of fullerene cytotoxicity on tumor cells by RNA-seq. Toxicology, 2013, 314, 183-192.	4.2	31
6	Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis. Journal of Molecular Medicine, 2020, 98, 595-612.	3.9	31
7	Pharmacogenetics of treatments for inflammatory bowel disease. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1209-1223.	3.3	27
8	MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases. World Journal of Gastroenterology, 2013, 19, 7947.	3.3	26
9	Long Non-Coding RNA GAS5 and Intestinal MMP2 and MMP9 Expression: A Translational Study in Pediatric Patients with IBD. International Journal of Molecular Sciences, 2019, 20, 5280.	4.1	24
10	Glucocorticoid pharmacogenetics in pediatric idiopathic nephrotic syndrome. Pharmacogenomics, 2015, 16, 1631-1648.	1.3	23
11	Microbiota and Drug Response in Inflammatory Bowel Disease. Pathogens, 2021, 10, 211.	2.8	23
12	Expression pattern of long non-coding RNA growth arrest-specific 5 in the remission induction therapy in childhood acute lymphoblastic leukemia. Journal of Medical Biochemistry, 2019, 38, 292-298.	1.7	22
13	Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 527-539.	3.3	20
14	Hydrophilic polymer coated monodispersed Fe <sub>3</sub> O <sub>4</sub> nanostructures and their cytotoxicity. Materials Research Express, 2014, 1, 015015.	1.6	19
15	Theophylline as a precision therapy in a young girl with PIK3R1 immunodeficiency. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 2165-2167.	3.8	19
16	Effects of Two Fullerene Derivatives on Monocytes and Macrophages. BioMed Research International, 2015, 2015, 1-13.	1.9	16
17	Identification and Characterization of a Novel Family of Cysteine-Rich Peptides (MgCRP-I) from <i>Mytilus galloprovincialis</i> . Genome Biology and Evolution, 2015, 7, 2203-2219.	2.5	16
18	Pharmacogenomics of Antibiotics. International Journal of Molecular Sciences, 2020, 21, 5975.	4.1	16

#	ARTICLE	IF	CITATIONS
19	RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A. <i>Metallomics</i> , 2015, 7, 1439-1450.	2.4	15
20	Differential expression of <sc>GAS</sc>5 in rapamycin-induced reversion of glucocorticoid resistance. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2016, 43, 602-605.	1.9	15
21	High-Throughput Sequencing of microRNAs in Glucocorticoid Sensitive Paediatric Inflammatory Bowel Disease Patients. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1399.	4.1	15
22	A Cationic [60] Fullerene Derivative Reduces Invasion and Migration of HT-29 CRC Cells in Vitro at Dose Free of Significant Effects on Cell Survival. <i>Nano-Micro Letters</i> , 2014, 6, 163-168.	27.0	14
23	Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019, 69, 474-479.	1.8	14
24	Azathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 Variants. <i>Genes</i> , 2019, 10, 277.	2.4	13
25	Serum Adalimumab Levels After Induction Are Associated With Long-Term Remission in Children With Inflammatory Bowel Disease. <i>Frontiers in Pediatrics</i> , 2021, 9, 646671.	1.9	13
26	Emerging Insights on the Interaction Between Anticancer and Immunosuppressant Drugs and Intestinal Microbiota in Pediatric Patients. <i>Clinical and Translational Science</i> , 2020, 13, 238-259.	3.1	12
27	Risk Factors and Outcomes of Thalidomide-induced Peripheral Neuropathy in a Pediatric Inflammatory Bowel Disease Cohort. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1810-1816.	1.9	11
28	Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease. <i>Clinical and Translational Science</i> , 2021, 14, 2184-2192.	3.1	11
29	MIF plasma level as a possible tool to predict steroid responsiveness in children with idiopathic nephrotic syndrome. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1675-1683.	1.9	9
30	Pharmacotranscriptomic Biomarkers in Glucocorticoid Treatment of Pediatric Inflammatory Bowel Disease. <i>Current Medicinal Chemistry</i> , 2018, 25, 2855-2871.	2.4	9
31	Pro-inflammatory effects of palytoxin: an in vitro study on human keratinocytes and inflammatory cells. <i>Toxicology Research</i> , 2016, 5, 1172-1181.	2.1	7
32	miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 361-374.	2.3	7
33	Patient-derived organoids for therapy personalization in inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2022, 28, 2636-2653.	3.3	7
34	Sedation and analgesia in children with cerebral palsy: a narrative review. <i>World Journal of Pediatrics</i> , 2019, 15, 432-440.	1.8	6
35	Pharmacogenetics of thiopurines. <i>Cancer Drug Resistance (Alhambra, Calif )</i> , 2019, 2, 256-270.	2.1	6
36	Clinical Application of Thiopurine Pharmacogenomics in Pediatrics. <i>Current Drug Metabolism</i> , 2020, 21, 53-62.	1.2	6

#	ARTICLE	IF	CITATIONS
37	Imidazo[2,1- <i>b</i> ]benzothiazol Derivatives as Potential Allosteric Inhibitors of the Glucocorticoid Receptor. ACS Medicinal Chemistry Letters, 2018, 9, 339-344.	2.8	4
38	Gender May Influence the Immunosuppressive Actions of Prednisone in Young Patients With Inflammatory Bowel Disease. Frontiers in Immunology, 2021, 12, 673068.	4.8	4
39	Role of tristetraprolin phosphorylation in paediatric patients with inflammatory bowel disease. World Journal of Gastroenterology, 2019, 25, 5918-5925.	3.3	4
40	Pharmacokinetics and pharmacodynamics of thiopurines in an <i>in vitro</i> model of human hepatocytes: Insights from an innovative mass spectrometry assay. Chemico-Biological Interactions, 2017, 275, 189-195.	4.0	3
41	A patent review of anticancer glucocorticoid receptor modulators (2014-present). Expert Opinion on Therapeutic Patents, 2020, 30, 313-324.	5.0	3
42	Extracellular Vesicles as Innovative Tools for Assessing Adverse Effects of Immunosuppressant Drugs. Current Medicinal Chemistry, 2022, 29, 3586-3600.	2.4	3
43	Atomic Force Microscopy Application for the Measurement of Infliximab Concentration in Healthy Donors and Pediatric Patients with Inflammatory Bowel Disease. Journal of Personalized Medicine, 2022, 12, 948.	2.5	3
44	Carbamazepine-induced thrombocytopenic purpura in a child: Insights from a genomic analysis. Blood Cells, Molecules, and Diseases, 2016, 59, 97-99.	1.4	2
45	Insights into the cellular pharmacokinetics and pharmacodynamics of thiopurine antimetabolites in a model of human intestinal cells. Chemico-Biological Interactions, 2021, 347, 109624.	4.0	2
46	Glucocorticoid Receptor Interacting Co-regulators: Putative Candidates for Future Drug Targeting Therapy. Mini-Reviews in Medicinal Chemistry, 2017, 17, 657-666.	2.4	2
47	Emerging molecular mechanisms underlying cancer metastasis: the rising role of the long non-coding RNA GAS5. Translational Cancer Research, 2016, 5, S827-S830.	1.0	2
48	MO006INFLAMMASOME ACTIVATOR NLRP3 HYPOMETHYLATION IS ASSOCIATED WITH GLUCOCORTICOID RESISTANCE IN PATIENTS WITH IDIOPATHIC NEPHROTIC SYNDROME. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0